Quality and Compliance

Quality and Compliance

As an CRDMO for global pharmaceutical companies, Lianhe Aigen have established an end to end quality management system based on international GxP regulations & guidelines to ensure patient safety and product quality, covering drug discovery and development, pre-clinical, clinical, and final commercial manufacturing. 

Quality and Compliance

Our facilities have been successfully inspected and approved by regulatory authorities such as FDA, NMPA, EMA, PMDA, TGA, KFDA, etc., as the proven track record for us to deliver our commitments to customers on time in full with quality. Lianhe Aigen are approved and commercially delivered APIs to more than 100 countries/markets, and served millions of patients around the world together with our customers.

Inspection History by Key Global Health Authorities

2023

US FDA inspection with no 483

2023

PMDA inspection

2023

NMPA inspection

2022

TGA inspection

2022

KFDA inspection

2022

NMPA inspection

2020

PMDA inspection

2020

NMPA inspection

2019

EMA inspection

2018

NMPA inspection

2017

US FDA inspection with no 483

2015

NMPA inspection

2010

NMPA inspection

2007

BfArM inspection

2005

NMPA inspection

GMP QMS

A comprehensive quality management system with FDA recommended 6 GMP elements,is established based on the concept of "quality by design" to drive the continuous improvement, then enhance patient safety and product quality.
-End to end quality management system to cover the whole product lifecycle
-Experienced quality professionals to ensure GMP compliant
-Comprehensive oversight system to ensure data integrity
-Dedicated intelligence monitoring team to catch up latest regulation requirements and best industry practices

Production System

Quality System

Packaging Labeling System

Material System

Facilities Equipment Systems

Laboratory Control System

GMP

GMP

GMP Certificates

Successfully passed the onsite inspections from the global key health authorities, such as NMPA, US FDA,EMA, TGA, PMDA, etc. and currently supply commercial APIs to more than 88 countries/areas. The submission and approval in other countries/areas are on-going.

2023 FDA EIR Cover Page General

2023 PMDA GMP certificate

2023 Written Confirmation for active substances exported to EU (Remibrutinib)

2022 Written confirmation for active substances exported to EU

2022 TGA GMP Certificate- Authorised 10 May 2023

2022 Korean Site registration notification

2021 Written confirmation for active substances exported to EU

2020 NMPA

2019 GMP-Certificate (EMA)(jiangkou)

Partnering With Us

Many years of CRO/CDMO experience and excellence solutions in certified quality management and advanced technologies ensure us as your trusted partner.

What Can We Help You?

We provide customers with one-stop CRDMO services covering the entire lifecycle of drugs.

Introduction

We use cookies on our website to better understand how you use our website. For more information about how we use cookies, please visit our Terms of Use and Legal Notices and Privacy Statement and Cookies Policy. By continuing to use this website without changing your settings, you will be deemed to have consented to our use of cookies.